3Mahlknecht U,Hoelzer D.Histone acetylation modifiers in the pathogenesis of malignant disease.Mol Med,2000,6 (8):623-644.
4Lin R J,Sternsdorf T,Tini M,et al.Transcriptional regulation in acute promyelocytic leukemia.Oncogene,2001,20(49):7204-7215.
5Vigushinl DM,Coombes RC.Histone deacetylase inhibitors in cancer treatment.Anticancer Drugs,2002,13 (1):1-13.
6Marks P,Rifkind RA,Richon VM,et al.Histone deacetylases and cancer:causes and therapies.Nat Rev Cancer,2001,1 (3):194-202.
7Blagosklonny MV,Robey R,Sackett DL,et al.Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation,mitotic arrest,and cytotoxicity.Mol Cancer Ther,2002,1 (11):937-941.
8Yu XD,Guo ZS,Mercu MG,et al.Modulation ofp53,ErbB1,ErbB2,and Raf-1 expression in lung cancer cells by depsipeptide FR901228.J Natl Cancer Inst,2002,94(7):504-513.
9Brinkman H,Dahler AL,Popa C,et al.Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts.J Biol Chem,2001,276(25):22491-22499.
10Di Gennaro E,Bruzzese F,Caraglia M,et al.Acetylation of proteins as novel target for antitumor therapy.Amino Acids,2004,26 (4):435-441.
